F8‐modified haematopoietic stem cells and FVIII‐corrected endothelial cells derived from haemophilia A patient‐induced pluripotent stem cells also provide long‐term phenotypic correction of haemophilia A.10, 11, 12These results suggest that ex vivo gene‐modified cell therapy is a promising strategy for haemophilia A treatment. Here, F8 is linked to hemophilia A.